Noble Financial Has Pessimistic View of UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at Noble Financial reduced their Q2 2027 earnings per share estimates for shares of Unicycive Therapeutics in a report released on Thursday, August 13th. Noble Financial analyst R. Leboyer now anticipates that the company will earn $0.75 per share for the quarter, down from their previous estimate of $0.91. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.49) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q3 2027 earnings at $1.06 EPS and Q4 2027 earnings at $1.24 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41.

A number of other research analysts also recently commented on the company. Benchmark lowered their price objective on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research note on Wednesday, July 1st. Zacks Research cut shares of Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings upgraded Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. Finally, HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Unicycive Therapeutics currently has an average rating of “Hold” and an average target price of $18.25.

Unicycive Therapeutics Stock Up 0.2%

Shares of UNCY stock opened at $5.40 on Friday. The company has a market cap of $147.91 million, a P/E ratio of -3.09 and a beta of 1.79. The business has a 50 day moving average of $5.97 and a two-hundred day moving average of $6.65. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares during the period. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. Vanguard Group Inc. raised its stake in Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after purchasing an additional 52,925 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $512,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $182,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.